李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议

智通财经07-17

智通财经APP讯，李氏大药厂(00950)发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. (Ashlins)订立独家许可协议。Ashlins为一家美国生物医药公司，并为Ashlins Pharmaceuticals Holdings, Inc.的全资附属公司，专注于收购、开发及商业化针对存在巨大医疗需求缺口的领域的经临床验证疗法。根据...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2652028501?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-17 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652028501","market":"us","top_or_hot":-1,"title":"李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，李氏大药厂(00950)发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. (Ashlins)订立独家许可协议。Ashlins为一家美国生物医药公司，并为Ashlins Pharmaceuticals Holdings, Inc.的全资附属公司，专注于收购、开发及商业化针对存在巨大医疗需求缺口的领域的经临床验证疗法。根据...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1469289.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-17 21:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1469289.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，李氏大药厂(00950)发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. (Ashlins)订立独家许可协议。Ashlins为一家美国生物医药公司，并为Ashlins Pharmaceuticals Holdings, Inc.的全资附属公司，专注于收购、开发及商业化针对存在巨大医疗需求缺口的领域的经临床验证疗法。根据...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1469289.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1469289.html","article_id":"2652028501","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652028501","pubTimestamp":1784295413,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，李氏大药厂 发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. 订立独家许可协议。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1587":"次新股","06622":"兆科眼科-B","BK1574":"生物医药B类股","00950":"李氏大药厂","BK1583":"高瓴概念"},"translate_title":"Lee's Pharmaceuticals (00950) entered into an exclusive licensing and supply agreement with ASHLINS for interferon ALPHA-2B products outside of Greater China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":1.5,"06622":1.5},"content_text":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. (Ashlins)订立独家许可协议。Ashlins为一家美国生物医药公司，并为Ashlins Pharmaceuticals Holdings, Inc.的全资附属公司，专注于收购、开发及商业化针对存在巨大医疗需求缺口的领域的经临床验证疗法。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。公司将收取一笔预付款项，并可按照特定成就，获得额外的开发里程碑付款及于商业化后获得年度商业化里程碑付款。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。Ashlins为一家美国生物医药公司，专注于收购、开发及商业化针对存在巨大医疗需求缺口的领域的经临床验证疗法。Ashlins的领导团队在美国监管策略、临床开发、FDA审批路径及商业化方面拥有丰富经验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652028501","isCrawlerRequest":true}